Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Dose CL-197 in Healthy Participants
NCT05944848Phase 1Completed
- Sponsor
- Genuine Biotech
- Start
- Nov 2022
- Primary completion
- Jan 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CL-197 in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by Genuine Biotech. Primary endpoint: Incidence of Treatment-Emergent Adverse Events as Assessed by The NCI CTCAE V5.0 Grading Criteria. Started Nov 2022; status: completed.
02
Drugs
CL-197
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05944848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05944848.